<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149682_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152626</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2013JP002233</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>1</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130107</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130121</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2013JP002233</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Tatsuo</reportergivename>
			<reporterfamilyname>Yoneda</reporterfamilyname>
			<reporterorganization>Nara medical University</reporterorganization>
			<reporterstate>Nara Prefecture</reporterstate>
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Ohara K et al. A Case of Promyelocytic Leukemia Developing during Immunosuppressor Therapy after Kidney Transplant. 97th Kinki Regional Meeting of Japanese Society of Neurology. 2012;28</literaturereference>
		</primarysource>
		<primarysource>
			<reportergivename>Keiye</reportergivename>
			<reporterfamilyname>Ohara</reporterfamilyname>
			<reporterorganization>Nara Medical University Hospital</reporterorganization>
			<reporterstate>Nara Prefecture</reporterstate>
			<reportercountry>JP</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>50</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Glomerulonephritis chronic</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>198310</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal failure chronic</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>198902</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal transplant</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>198402</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Chronic allograft nephropathy</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>198706</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Transplant rejection</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal transplant</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20070523</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Non-HIV-related PML</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Progressive multifocal leukoencephalopathy</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Progressive multifocal leukoencephalopathy</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>JCV level (1.26 x 10E4 copies/ml)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>JC virus infection</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>JC virus infection</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201202</reactionstartdate>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Left facial numbness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Numbness in face</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypoaesthesia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201202</reactionstartdate>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Muscular weakness of the left arm</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Muscle weakness upper limb</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Muscular weakness</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201202</reactionstartdate>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Creatinine level transiently increased</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Creatinine increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood creatinine increased</reactionmeddrapt>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>Nuclear magnetic resonance imaging brain</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Polymerase chain reaction</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NEORAL</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>CICLOSPORIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypoaesthesia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypoaesthesia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>JC virus infection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>JC virus infection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Muscular weakness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Muscular weakness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Progressive multifocal leukoencephalopathy</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Progressive multifocal leukoencephalopathy</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NEORAL</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>CICLOSPORIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypoaesthesia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypoaesthesia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>JC virus infection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>JC virus infection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Muscular weakness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Muscular weakness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Progressive multifocal leukoencephalopathy</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Progressive multifocal leukoencephalopathy</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>CELLCEPT</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MYCOPHENOLATE MOFETIL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>SIMULECT</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>20 mg, UNK</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>BASILIXIMAB</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PREDNISOLONE</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugstructuredosagenumb>5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>5 mg, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>PREDNISOLONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PLASMAPHERESIS</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transplant rejection</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>NO INGREDIENTS/SUBSTANCES</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>IMMUNOGLOBULINS</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transplant rejection</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>NO INGREDIENTS/SUBSTANCES</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2013JP002233 is an initial literature report received on 07 Jan 2013 and follow up report received from physician on 21 Jan 2013. This report refers to a 50-year-old female patient who had chronic glomerulonephritis and was undergoing hemodialysis in Oct 1983. In Feb 1984 she underwent renal transplant for chronic renal failure from her father. In Jun 1987, she developed chronic allograft nephropathy and hence hemodialysis was introduced again. In Feb 1989, extirpation of renal transplant done. On 23 May 2007, she underwent again cadaveric renal transplant. She was started on Neoral (ciclosporin), Simulect (Basiliximab), Co-suspect Cellcept and prednisolone. After an unknown duration, she developed antibodymediated rejection which was treated with plasmapheresis and IV globulins. Fifteen day later hemodialysis was withdrawn. In Feb 2012, the patient was aware that the face transiently felt numb on the left side and muscular weakness of the left arm (patient had difficulty gripping things). And thus, the patient visited a local clinic. Magnetic resonance imaging (MRI) revealed high signal intensity area under the right-sided parietal cortex, right frontal operculum and right angular gyrus on T2 weighted image, suggesting Progressive multifocal leukoencephalopathy (PML). The patient was transferred to the reporting physician&#8217;s hospital. Despite treatment with Aciclovir (aciclovir) which was initiated at previous clinic, worsening was found on image; Cellcept was stopped. Polymerase chain reaction (PCR) with the spinal fluid showed HIV negative but had high cerebrospinal fluid JCV level (1.26 x 10E4 copies/ml). A diagnosis of non-HIV-related PML was made. Neoral was stopped. The dose of prednisolone was reduced to 5mg. Since that, although the creatinine level transiently increased, the function of the renal transplant had been stable, and the lesion of the head had diminished on image. Therefore, on 72nd day of the disease, the patient was discharged from hospital. As of the time of this report, the patient was followed up on an outpatient basis, receiving Mizoribine (mizoribine) and Neoral. Events were considered as serious and life threatening by reporting physician. The physician commented that "Cellcept (mycophenolate mofetil) was a causal factor of Non-HIV-related PML and causal relationship between this event and Neoral was uncertain"

Follow-up literature report received on 21 Jan 2013: Updated medical history, suspect brand name, new co-medication (prednisone, Simulect) Changed concomitant to suspect product (CellCept), Event onset date and outcome, action taken with suspect product, treatment given, new events (muscular weakness, numbness, creatinine level transiently increased), lab data and author comment.</narrativeincludeclinical>
				<sendercomment>MAC: The event progressive JC virus infection is consistent with immunosuppressant drugs known pharmacology; hence a causal relationship to drug cannot be excluded. Hypoaesthesia  and muscular weakness can be symptoms of neurological manifestation of JC virus infection.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
